Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
about
Tau PET imaging: present and future directions.Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain NetworksCurrent Understanding of Neurodegenerative Diseases Associated With the Protein Tau.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Imaging tau pathology in Parkinsonisms.Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's caseComparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.New advances in tau imaging in parkinsonism.In Vivo Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line.Small-molecule PET Tracers for Imaging Proteinopathies.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Corticobasal degeneration: key emerging issues.Tau Filaments and the Development of Positron Emission Tomography Tracers.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.PET imaging of tau protein targets: a methodology perspective.Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.Amyloid-Beta Radiotracer [18F]BF-227 Does Not Bind to Cytoplasmic Glial Inclusions of Postmortem Multiple System Atrophy Brain Tissue.Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.The development and validation of tau PET tracers: current status and future directions
P2860
Q34680852-EA9EC52F-8722-4944-8B58-21144BC999BBQ37731919-45AF51A3-092C-4D05-B31C-34BA9F548331Q38640294-BAC9B08F-83A5-458F-B959-167A81E6481EQ38666247-285D2E96-28FA-4383-91E3-F064227DE16AQ38821003-206C420A-502F-42E7-B22F-D2E58D51F9ACQ39303669-FA3A9E38-35BC-453B-89C6-00E5DABE88BBQ39419877-B9285FC8-0709-4DE0-9D63-A267A25B085DQ42672461-DC6FAC02-C793-4766-A02C-5FBAFC2AB4CBQ47140361-518FAC6C-29A8-4EAF-AA68-6095AFF33C9FQ47329627-FDAD8627-0D90-43BB-808A-BD34B021DEEBQ47835964-E9F6BF9C-A857-4BF0-94AA-A1CF5368C1E6Q47926474-F3613546-83C1-43BA-BDE5-31608C73466BQ49295547-28BD5C9A-6567-42D8-B30F-8141C836B95AQ50074075-8154AD21-1725-42AF-AE0B-0BDD250F7BC8Q50350781-CC277836-7910-4959-A277-B0606BD499E9Q50532471-4059A44B-0A4E-4DAA-AD45-789789A853DBQ51766173-F13CBE30-E44E-45A9-9950-DA934F787939Q52344625-7DABAA4A-B5ED-4EFE-9F59-3F8DC75906DBQ55119582-86B3CE47-5CB7-44A1-BFAE-032526C8C3E9Q55254017-72739B7C-52B7-452D-B67D-2B36D1846BAEQ55416644-7D4A961B-27A6-4BFC-A0F7-F1E14F8078A6Q56594907-38BA3A0B-2C56-4BFC-A5EB-438C0EABAD87
P2860
Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@en
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@nl
type
label
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@en
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@nl
prefLabel
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@en
Distinct binding of PET ligand ...... neurodegenerative tauopathies.
@nl
P2093
P2860
P50
P356
P1433
P1476
Distinct binding of PET ligand ...... neurodegenerative tauopathies
@en
P2093
Dennis W Dickson
John C van Swieten
John Q Trojanowski
Katsushi Kumata
Makoto Higuchi
Mari Yoshida
Ming-Rong Zhang
Naruhiko Sahara
P2860
P304
P356
10.1093/BRAIN/AWW339
P407
P577
2017-03-01T00:00:00Z